Adam Grossman: I would make a note, Elliot, I’ll try to touch them all. If I miss something, just ask. But no, thanks for the question. Not to sound like a broken record, but demand is strong. As I know you know, but for those who may not, who are listening, typically, if you’re a primary immune-deficient patient, you have a genetic defect that requires you to get IG infusions every 3 to 4 weeks for the rest of your life. If you have secondary immune deficiency, depending upon your condition, if it’s an organ transplant, you’re immune compromised for your life, so you typically may stay on IG for longer periods. If you had a bone marrow transplant or maybe you’re getting some type of short-term monoclonal therapy that renders you to be immune compromised, you may be on IG for a shorter period of time.
But what we’re seeing is we’re seeing continued use by our existing customers. Obviously, there’s growth. We’ve been ramping up our production throughput over the last 1 year, 1.5 years. And as we said last year, and as I said in the prepared remarks, we’ve got unique visibility because the product that we’re selling today, we made last year in the second quarter. So we certainly have the inventory there. I mean we ended the year $160-ish million of inventory. And we feel that, that certainly will support $210 million or more in top line revenue. But it’s durable, Elliot. And we’re seeing continued utilization by existing patients and prescribers, and we are seeing new prescribers being added every month, every quarter. We’re also self-regulating.
I mean we kind of live in this world that’s a little different than some of the larger players in the immunoglobulin space. Again, we’re really 99% outpatient. We work with great specialty pharmacies, great home infusion and freestanding ambulatory infusion clinics as well as doctors’ offices that do IG infusion. And we’re really building brand loyalty. We’re building great relationships with our prescribers and these infusion pharmacies. And we’re able to really I don’t want to say choose who our customers are, but we’re working with folks that, a, pay their bills on time; and b, order and stock inventory according to contract. It’s a symbiotic relationship. We guarantee the continuity of care with our supply, and they have it available for their patients when they need it.
Again, we’re the only IG manufacturer who’s not pushing any other plasma-derived therapy. So we don’t have to sell albumin. We don’t have to sell coagulation factors. We’re not selling any other novel unique plasma protein. So we really feel very good about the position and the demand utilization. The inventories in the channel are normal, if not a little bit thin, depending upon the vial presentation. But I can tell you that we are committed here and we are pushing more plasma into the plant than ever before to ensure that continued growth trajectory for both products. You asked a question about persistence of patients on ASCENIV therapy. A lot of people ask us that same question, Elliot. I know that they ask you that question, and I’m sure that they ask the other analysts as well.
And what I can say is, yes, the patients that are starting on therapy, based on the input and data that I have available to me, the majority of patients that were on ASCENIV at the end of last year are continuing on therapy at the beginning of this year. I’m aware of very few patients that have come off therapy and switched back to normal IG. Obviously, as people change their insurance or as they move to different states, as they have changes in their life, things certainly happen. But I can tell you that the patients that are being monitored by the clinicians are remaining on therapy. It’s durable. There’s no seasonality in the utilization of ASCENIV. I think that’s something that I think is a question we also get, Elliot. What more can I say?
